VITROS IMMUNODIAGNOSTIC PRODUCTS ANTI-HBC REAGENT PACK/CALIBRATOR

Test, Hepatitis B (b Core, Be Antigen, Be Antibody, B Core Igm)

FDA Premarket Approval P030024

This medical device has supplements. The device description/function or indication may have changed. Be sure to look at the supplements to get an up-to-date information on device changes. The labeling included below is the version at time of approval of the original pma or panel track supplement and may not represent the most recent labeling.

Pre-market Approval Supplement Details

Approval for the vitros immunodiagnostic products anti-hbc reagent pack and vitros immunodiagnostic products anti-hbc calibrator. These devices are indicated for: 1) vitros immunodiagnostic products anti-hbc reagent pack is indicated for the in vitro qualitative detection of total antibody (igg and igm) to hepatitis b core antigen (total anti-hbc) in human adult and pediatric serum and plasma (edta and citrate) and neonate serum using the vitros eci immunodiagnostic system. Assay results, in conjunction with other serological and clinical information, may be used for the laboratory diagnosis of individuals with acute or chronic hepatitis b, or recovery from hepatitis b infection. The presence of anti-hbc may be used as an aid in the determination of exposure to hbv infection for individuals prior to hbv vaccination. 2) vitros immunodiagnostic products anti-hbc calibrator is indicated for use in the calibration of the vitros eci immunodiagnostic system when used for the in vitro qualitative detection of total antibody (igg and igm) to hepatitis b core antigen (total anti-hbc) in human adult and pediatric serum and plasma (edta and citrate) and neonate serum using vitros anti-hbc reagent packs.

DeviceVITROS IMMUNODIAGNOSTIC PRODUCTS ANTI-HBC REAGENT PACK/CALIBRATOR
Classification NameTest, Hepatitis B (b Core, Be Antigen, Be Antibody, B Core Igm)
Generic NameTest, Hepatitis B (b Core, Be Antigen, Be Antibody, B Core Igm)
ApplicantORTHO-CLINICAL DIAGNOSTICS
Date Received2003-06-19
Decision Date2004-03-04
Notice Date2004-08-04
PMAP030024
SupplementS
Product CodeLOM
Docket Number04M-0341
Advisory CommitteeMicrobiology
Expedited ReviewNo
Combination Product No
Applicant Address ORTHO-CLINICAL DIAGNOSTICS 100 Indigo Creek Dr. rochester, NY 14626-5101
Summary:Summary of Safety and Effectiveness
Labeling: Labeling
Approval Order: Approval Order

Supplemental Filings

Supplement NumberDateSupplement Type
P030024Original Filing
S029 2019-05-21 30-day Notice
S028 2018-10-16 Normal 180 Day Track No User Fee
S027 2018-09-17 30-day Notice
S026 2018-02-21 Normal 180 Day Track No User Fee
S025 2018-01-09 Normal 180 Day Track No User Fee
S024 2017-08-07 30-day Notice
S023 2015-08-10 30-day Notice
S022 2015-06-25 30-day Notice
S021 2013-08-12 30-day Notice
S020 2012-10-17 30-day Notice
S019 2012-05-04 30-day Notice
S018 2012-01-30 30-day Notice
S017 2011-10-05 Real-time Process
S016 2011-05-16 135 Review Track For 30-day Notice
S015 2011-04-15 30-day Notice
S014 2010-12-06 135 Review Track For 30-day Notice
S013 2010-10-18 30-day Notice
S012 2009-12-01 Normal 180 Day Track No User Fee
S011 2009-03-06 30-day Notice
S010 2009-02-12 Normal 180 Day Track
S009 2008-11-13 Normal 180 Day Track No User Fee
S008 2008-01-23 30-day Notice
S007 2007-12-10 Real-time Process
S006 2007-05-11 30-day Notice
S005 2006-05-15 30-day Notice
S004 2005-11-14 30-day Notice
S003 2005-04-08 Special (immediate Track)
S002 2004-10-26 30-day Notice
S001 2004-03-17 30-day Notice

NIH GUDID Devices

Device IDPMASupp
10758750002771 P030024 021
10758750001224 P030024 021
10758750001217 P030024 021

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.